| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: invention refers to pharmaceuts. What is described is a pharmaceutical preparation containing 1-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)-2-(3,5-dichloro-1-oxypyridin-4-yl)ethyl ester (-)-3-cyclopropylmethoxy-4-methansulphonylaminobenzoic acid, surfactant, co-solvent and propellant. The surfactant is specified in polyethylene glycol 600 (PEG600) or polyvinylpyrrolidone (PVP), or a mixture thereof. The co-solvent represents ethanol. The propellant represents hydrofluoralkan specified in a group containing 1,1,1,2-tetrafluorethane (HFA134a), 1,1,1,2,3,3,3-heptafluor-n-propane (HFA227) and a mixture thereof. n EFFECT: invention provides implementing the above application. n 6 cl, 7 tbl, 4 ex |